New investment in Proton Intelligence
We Venture Capital is pleased to announce its investment into Proton Intelligence in a heavily oversubscribed $6.95m Seed round alongside Tenmile, SOSV, LongVC, 15th Rock, Exor Ventures, Trampoline Venture Partners and others.
The company is developing the world´s first non invasive CKM™ for monitoring potassium levels of kidney patients. 1/3 of patients with chronic kidney disease or heart failure unnecessarily stop life-saving therapy after a high potassium event, which ultimately leads to a c.40% increase in 6-month mortality. Proton’s CKM™ technology aims to provide providers and patients accurate, remote, continuous potassium levels allowing precise treatment of these patients.
We Venture Capital have been impressed by this true breakthrough in electrolyte sensing capability, which will fulfil a critical gap in the current care continuum for many patients at risk from dyskalemia. We look forward to working with the Proton Intelligence team on the next phase of their journey.
Louise Warme, Head of We Venture Capital
The company is headquartered in Vancouver, Canada with R&D operations in Melbourne, Australia.
Proton Intelligence´s seed round is a big step forward for people living with cardio-kidney-metabolic conditions — bringing us closer to direct, accurate and real-time potassium monitoring to better health outcomes.
Sahan Ranamukhaarachchi, CEO of Proton Intelligence
About We Venture Capital
We Venture Capital is a specialized fund investing in diagnostics, as well as tools and digital solutions in the diagnostics area. Being the corporate investment arm of Werfen, a worldwide leader in specialized diagnostics, We Venture Capital is an active investor, leveraging the network and knowledge from Werfen to the benefit of our investments.
We invest in and partner with early-stage startups close to market entry or early scale-ups, working close with our portfolio to support their growth over time. We are firm believers of technical advancement as a means to improve patient outcomes and revolutionize healthcare.
About Proton Intelligence
Proton Intelligence Inc. is headquartered in Vancouver, Canada, with R&D operations in Melbourne, Australia. The company is revolutionizing healthcare with its continuous electrolyte monitoring technology, starting with CKM™ for potassium (akin to continuous glucose monitoring in diabetes). The CKM™ platform addresses a critical challenge in cardio-kidney-metabolic disease management by enabling the safe implementation of optimal medical therapies.
For more information, please contact:
Rory St Clair
Email: marketing@protonintel.com